| Assay ID | Title | Year | Journal | Article |
|---|
| AID540225 | Volume of distribution at steady state in dog after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID540224 | Clearance in dog after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID220465 | Inhibition of alphaV-beta3 integrin binding | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID540223 | Volume of distribution at steady state in rat after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID235997 | Bioavailability in rhesus monkey | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID170966 | Inhibitory effect of 30 mpk compound b.i.d. for 28 days was determined by bone mineral density in ovariectomized female rat | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID662308 | Antagonist activity at integrin alpha5beta1 in human K562 cells assessed as inhibition of cell adhesion | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2. |
| AID236166 | Clearance value in rat | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID662312 | Antagonist activity at integrin alphaVbeta3 in human A375M cells assessed as cell adhesion to fibrinogen in presence of Mg2+ | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2. |
| AID10765 | Plasma clearance in rat was determined | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID32989 | Inhibition of alphaIIb-beta3 integrin mediated platelet aggregation | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID237547 | Effect was measured in male rats on free steady state serum concentration | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID482457 | Antiosteoporotic activity in rat assessed as increase in distal femoral metaphysis bone mineral density at 10 mg/kg BID for 28 days relative to control | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID482459 | Antiosteoporotic activity in rhesus monkey assessed as decrease in bone resorption-associated urinary NTX-1 level at 15 mg/kg QD for 14 days | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID237476 | Effect was measured in male rats on distal femoral metaphysis bone mineral density | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID482460 | Antiosteoporotic activity in postmenopausal woman with osteoporosis assessed as increase in lumbar spine bone mineral density at 200 mg/kg BID for 12 months | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID540222 | Clearance in rat after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID482456 | Plasma protein binding in human | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID482478 | Inhibition of integrin alphaVbeta3 | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID9695 | Half life of compound was determined in dog | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID19459 | Partition coefficient (logP) | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID170965 | Inhibitory effect of 10 mpk compound b.i.d. for 28 days was determined by bone mineral density in ovariectomized female rat | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID1647693 | Inhibition of human integrin alphavbeta3 expressed in HEK293 cells assessed as reduction in cell adhesion to fibrinogen preincubated for 20 mins followed by phosphatase substrate addition and measured after 1 hr by spectrophotometry | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
| Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations. |
| AID482461 | Antiosteoporotic activity in postmenopausal woman with osteoporosis assessed as increase in hip bone mineral density at 200 mg/kg BID for 12 months | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID7597 | Percent binding of compound towards human plasma protein was determined | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID662313 | Antagonist activity at integrin alphavbeta3alpha5beta1 in human A375M cells assessed as inhibition of cell adhesion to fibronectin in presence of Mg2+ | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2. |
| AID482453 | Clearance in po dosed dog | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID237110 | Half life in rhesus Monkey | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID237065 | Half life in rat | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID540226 | Clearance in monkey after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID482451 | Half life in po dosed rat | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID7344 | Bioavailability of compound was determined in rhesus monkey | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID10442 | Half life of compound was determined in rat | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID540229 | Volume of distribution at steady state in human after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID235964 | Bioavailability in dog | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID540227 | Volume of distribution at steady state in monkey after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID482454 | Half life in po dosed dog | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID8524 | Plasma clearance in dog was determined | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID9118 | Bioavailability in dog | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID7551 | Half life of compound was determined in rhesus monkey | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID482458 | Antiosteoporotic activity in rat assessed as increase in distal femoral metaphysis bone mineral density at 30 mg/kg BID for 28 days relative to control | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID237430 | Partition coefficient (logP) | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID482452 | Oral bioavailability in rat | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID237063 | Half life in dog | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID662314 | Antagonist activity at integrin alpha5beta1 in human A375M cells assessed as inhibition of cell adhesion in presence of Mg2+ and MK-0429 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2. |
| AID220477 | Selectivity for alphaV-beta3 over alphaV-beta5 integrins | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID235966 | Bioavailability in rat | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID236174 | Clearance value in rhesus monkey | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID243133 | In vitro binding affinity against integrin Alpha-v Beta3 receptor in SPA assay | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID482455 | Oral bioavailability in dog | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID482450 | Clearance in po dosed rat | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID482462 | Antiosteoporotic activity in postmenopausal woman with osteoporosis assessed as increase in femoral neck bone mineral density at 200 mg/kg BID for 12 months | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID12964 | Bioavailability in rat | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID236165 | Clearance value in dog | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID170967 | distal femoral metaphysis bone mineral density in young male rat after constant infusion of compound was determined | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| AID662315 | Selectivity ratio of IC50 for integrin alphavbeta3alpha5beta1-mediated human A375M cells adhesion to fibronectin in absence of MK-0429 to IC50 for integrin alpha5beta1-mediated human A375M cells adhesion to fibronectin in presence of MK-0429 | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
| Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2. |
| AID482465 | Selectivity for integrin alphaVbeta3 over integrin alphaVbeta5 | 2010 | Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
| Emerging targets in osteoporosis disease modification. |
| AID236276 | Human plasma binding affinity was determined | 2004 | Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17
| Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative. |
| AID540228 | Clearance in human after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
| Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID10256 | Plasma clearance in rhesus monkey was determined | 2003 | Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
| Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |